Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$2.55 +0.4%	$2.82	$1.84 ▼ $5.31	$88.45M	1.3	516,974 shs	432,634 shs
RIGL Rigel Pharmaceuticals	$37.89 +3.6%	$21.46	$11.88 ▼ $38.35	$679.75M	1.21	275,091 shs	779,060 shs
VSTM Verastem	$7.73 -3.6%	$5.48	$2.24 ▼ $9.10	$475.74M	0.83	1.77 million shs	3.57 million shs
XOMA XOMA Royalty	$31.59 +2.3%	$26.15	$18.35 ▼ $35.00	$378.04M	1	43,501 shs	93,756 shs

10 Stocks Set to Soar in Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	+4.10%	-3.79%	-7.64%	-6.96%	-41.68%
RIGL Rigel Pharmaceuticals	+5.97%	+22.71%	+89.04%	+85.31%	+188.71%
VSTM Verastem	-2.31%	+40.21%	+61.69%	+1.13%	+222.09%
XOMA XOMA Royalty	+8.54%	+16.92%	+11.28%	+14.83%	+16.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHV Achieve Life Sciences	2.0063 of 5 stars	3.8	2.0	0.0	1.9	0.0	0.6
RIGL Rigel Pharmaceuticals	1.6745 of 5 stars	1.2	1.0	0.0	2.6	1.7	3.1
VSTM Verastem	3.1087 of 5 stars	3.5	3.0	0.0	3.0	2.5	0.6
XOMA XOMA Royalty	4.3956 of 5 stars	3.5	4.0	3.0	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.50	Strong Buy	$14.33	465.42% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$38.20	1.02% Upside
VSTM Verastem	3.00	Buy	$13.29	71.76% Upside
XOMA XOMA Royalty	3.00	Buy	$69.50	118.52% Upside

Current Analyst Ratings Breakdown

Latest ACHV, RIGL, XOMA, and VSTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$12.00 ➝ $13.00
8/6/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $32.00
6/25/2025	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$16.00 ➝ $12.00
5/28/2025	XOMA XOMA Royalty	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$104.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	$1.20 per share	N/A
RIGL Rigel Pharmaceuticals	$179.28M	3.78	$1.18 per share	32.00	$4.57 per share	8.27
VSTM Verastem	$10K	47,601.19	N/A	N/A	$0.59 per share	13.11
XOMA XOMA Royalty	$13.05M	29.17	N/A	N/A	$6.95 per share	4.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$39.83M	-$1.46	N/A	N/A	N/A	N/A	-193.49%	-116.68%	N/A
RIGL Rigel Pharmaceuticals	$17.49M	$5.41	6.99	36.01	N/A	36.51%	438.89%	57.03%	N/A
VSTM Verastem	-$130.64M	-$3.28	N/A	N/A	N/A	N/A	-2,003.62%	-119.85%	N/A
XOMA XOMA Royalty	-$13.82M	-$1.55	N/A	N/A	N/A	-13.04%	-12.43%	-4.85%	N/A

Latest ACHV, RIGL, XOMA, and VSTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	XOMA XOMA Royalty	-$0.12	$0.48	+$0.60	$0.44	$9.39 million	$13.13 million
8/7/2025	Q2 2025	ACHV Achieve Life Sciences	-$0.37	-$0.37	N/A	-$0.37	N/A	N/A
8/7/2025	Q2 2025	VSTM Verastem	-$0.64	-$0.39	+$0.25	-$0.39	$6.01 million	$2.14 million
8/5/2025	Q2 2025	RIGL Rigel Pharmaceuticals	$1.97	$3.28	+$1.31	$3.28	$64.58 million	$101.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A
XOMA XOMA Royalty	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.21	6.64	6.64
RIGL Rigel Pharmaceuticals	0.46	2.02	1.90
VSTM Verastem	2.06	3.46	3.50
XOMA XOMA Royalty	1.18	5.54	5.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
RIGL Rigel Pharmaceuticals	66.23%
VSTM Verastem	88.37%
XOMA XOMA Royalty	95.92%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	3.00%
RIGL Rigel Pharmaceuticals	9.48%
VSTM Verastem	2.10%
XOMA XOMA Royalty	9.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	20	34.69 million	33.64 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.94 million	16.24 million	Optionable
VSTM Verastem	50	61.54 million	60.25 million	Optionable
XOMA XOMA Royalty	10	11.97 million	10.88 million	Optionable

ACHV, RIGL, XOMA, and VSTM Headlines

Recent News About These Companies

LAVA Therapeutics Announces Acquisition by XOMA Corporation

1 hour ago | tipranks.com

Xoma Corp. Reports Strong Earnings Growth in 2025

August 14 at 4:26 AM | msn.com

LAVA Therapeutics Enters Agreement to Be Acquired by XOMA Royalty Corporation and Announces Discontinuation of LAVA-1266 Development

August 13 at 5:42 PM | quiverquant.comQ

Cautious Hold Rating on Xoma Amid Strategic Acquisitions and Uncertain Growth Outlook

August 13 at 11:42 AM | tipranks.com

XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates

August 13 at 9:55 AM | zacks.com

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

August 13 at 7:30 AM | globenewswire.com

XOMA Royalty Corporation: XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

August 11 at 2:16 PM | finanznachrichten.de

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

August 11 at 9:15 AM | finance.yahoo.com

XOMA Royalty (XOMA) Projected to Post Earnings on Tuesday

August 11 at 2:12 AM | americanbankingnews.com

XOMA Royalty (NASDAQ:XOMA) Upgraded to "Buy" at Wall Street Zen

August 11 at 2:21 AM | marketbeat.com

Institutional investors own a significant stake of 43% in XOMA Royalty Corporation (NASDAQ:XOMA)

August 10, 2025 | finance.yahoo.com

CM Management LLC Grows Stake in XOMA Royalty Corporation (NASDAQ:XOMA)

August 7, 2025 | marketbeat.com

XOMA Royalty (XOMA) Projected to Post Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

I'm Staying Neutral On XOMA Royalty After The LAVA And HilleVax Deals

August 6, 2025 | seekingalpha.com

HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

August 5, 2025 | businesswire.com

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.

August 5, 2025 | prnewswire.com

Hold Rating on XOMA’s Acquisition of LAVA Therapeutics: Valuation and Risks Assessed

August 5, 2025 | tipranks.com

XOMA Royalty (NASDAQ:XOMA) Cut to "Hold" at Wall Street Zen

August 5, 2025 | americanbankingnews.com

LAVA Therapeutics stock rises on acquisition deal with XOMA Royalty

August 4, 2025 | investing.com

Hillevax stock rises after XOMA Royalty announces acquisition

August 4, 2025 | investing.com

XOMA Royalty Corporation Enters Definitive Share Purchase Agreement to Acquire LAVA Therapeutics N.V.

August 4, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV, RIGL, XOMA, and VSTM Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$2.55 +0.01 (+0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$2.53 -0.02 (-0.82%)

As of 05:12 PM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Rigel Pharmaceuticals NASDAQ:RIGL

$37.89 +1.31 (+3.58%)

Closing price 04:00 PM Eastern

Extended Trading

$37.98 +0.09 (+0.24%)

As of 05:32 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Verastem NASDAQ:VSTM

$7.73 -0.29 (-3.62%)

Closing price 04:00 PM Eastern

Extended Trading

$7.73 0.00 (0.00%)

As of 05:42 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

XOMA Royalty NASDAQ:XOMA

$31.59 +0.70 (+2.27%)

Closing price 04:00 PM Eastern

Extended Trading

$31.58 -0.01 (-0.03%)

As of 04:20 PM Eastern

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time